Legal Representation
Attorney
Cynthia Moyer
USPTO Deadlines
Next Deadline
2620 days remaining
Section 8 & 9 (20-Year) Renewal Due (Based on registration date 2012-09-11)
Due Date
September 11, 2032
Grace Period Ends
March 11, 2033
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| Jul 1, 2024 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Jul 1, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Jul 1, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Jul 1, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jan 11, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Jan 11, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Jan 11, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Jan 11, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jan 11, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Mar 11, 2023 | RNL1 | Q | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) |
| Mar 11, 2023 | 89AG | O | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED |
| Mar 11, 2023 | NA89 | E | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED |
| Mar 10, 2023 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Aug 23, 2022 | E89R | I | TEAS SECTION 8 & 9 RECEIVED |
| Sep 11, 2021 | REM2 | E | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED |
| Oct 4, 2019 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Oct 4, 2019 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jul 26, 2018 | NA85 | E | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED |
| Jul 26, 2018 | C15A | O | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. |
| Jul 24, 2018 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Jul 12, 2018 | E815 | I | TEAS SECTION 8 & 15 RECEIVED |
| Jul 12, 2018 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Sep 11, 2017 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| Aug 16, 2017 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Aug 16, 2017 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Oct 12, 2016 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Oct 12, 2016 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jun 5, 2015 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Jun 5, 2015 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Sep 11, 2012 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Aug 10, 2012 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Aug 9, 2012 | REGV | O | LAW OFFICE REGISTRATION REVIEW COMPLETED |
| Jul 27, 2012 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Jul 24, 2012 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| Jul 20, 2012 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Jun 27, 2012 | IUAF | S | USE AMENDMENT FILED |
| Jun 27, 2012 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| May 8, 2012 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Mar 13, 2012 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Mar 13, 2012 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Feb 22, 2012 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Feb 6, 2012 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Feb 6, 2012 | ALIE | A | ASSIGNED TO LIE |
| Feb 1, 2012 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Jan 21, 2012 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jan 20, 2012 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jan 19, 2012 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jan 19, 2012 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jan 13, 2012 | GEAN | O | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED |
| Jan 13, 2012 | EPEN | O | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY |
Detailed Classifications
Class 042
pharmaceutical research and development services
First Use Anywhere:
Jan 5, 2012
First Use in Commerce:
Jan 5, 2012
Additional Information
Design Mark
The mark consists of the word "NAVIDEA" over the word "BIOPHARMACEUTICALS" with a split arrowhead design to the right of "NAVIDEA".
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOPHARMACEUTICALS"